PAK5和P-gp与上皮性卵巢癌相关性的临床研究  

作　　者：邹竞慧 李笛悠[1] 张萍[1] 

机构地区：[1]上海交通大学医学院附属新华医院妇科,200092

出　　处：《浙江临床医学》2016年第12期2196-2198,共3页Zhejiang Clinical Medical Journal

摘　　要：目的研究PAK5和P-gp与EOC临床因素的相关性，为预测上皮性卵巢癌（EOC）进展及患者预后提供指导。方法回顾分析自2013年1月至2015年6月接受手术治疗且经病理确诊为EOC的患者，回顾整理患者的病理类型、FIGO分期、细胞分化和化疗耐药等临床资料，并用免疫组织化学方法测定EOC中PAK5和P-gp的表达量，分析PAK5和P-gP在EOC组织中的表达情况及与临床资料的关系。结果在EOC患者组织中，单因素分析，PAK5的阳性率在FIGO分期晚期组高于FIGO早期组，细胞低分化组高于中高分化组（P均〈0．01）。PAK5与病理类型阳性率无明显差异（P〉0．05）。P-gp的阳性率在FIGO分期晚期组高于FIGO早期组，细胞低分化组高于中高分化组（P均〈0．01）。PAK5与病理类型阳性率无明显差异（P〉0．05）。PAK5阳性率在耐药组高于敏感组，差异有统计学意义（P〈0．05）。P-gp阳性率在耐药组高于敏感组。差异有统计学意义（P〈0．001）。结论PAK5和P-gP在EOC组织中均呈高表达，PAK5和P-gp阳性表达量与FIGO分期、细胞分化不良和化疗耐药有关，对预测上皮性卵巢癌疾病发展及患者预后有重要意义。Objective To investigate the clinical factors correlation of PAK5 and P-gp in EOC, in order to provide guidance to predict disease progress and prognosis of EOC patients. Methods Research Objects were the patients who accepted surgery in Department of Gynecology and were diagnosed epithelial ovarian cancer definitely by pathological diagnosis in our hospital from January 2013 to June 2015. We carried out a retrospective study of the clinical factors, such as, pathological type, FIGO stages, cell differentiation, chemoresisitance and so on. Immunohistochemistry （IHC） staining was performed to investigate the expression of PAK5 and P-gp. Finally, we analyzed the expression of PAK5 and P-gp in EOC tissue and the correlation of PAK5 and P-gp and the above clinical factors. Results 1.The positive rate of PAK5 in FIGO advanced group was higher than in FIGO early group, the positive rate of PAK5 in poor cell differentiation group was higher than in well and moderate cell differentiation group （ 81.8%vs 47.3% ） , differences were statistically significant in the above factors （ P〈0.01 ） . However, there was not significant difference in positive expression rate of PAK5 when grouped by pathological type （ P〉0.05 ） .The positive rate of P-gp in FIGO advanced group was higher than in FIGO early group, the positive rate of P-gp in poor cell differentiation group was higher than in well and moderate cell differentiation group, differences were statistically significant in the above factors （P〈0.01） . However, there was not significant difference in positive expression rate of P-gp when grouped by pathological type （ P〉0.05 ） .2.The positive rate of PAK5 in chemoresistance group was higher than in chemosensitivity group, differences were statistically significant in the above factors （ P〈0.05 ） . The positive rate of P-gp in chemoresistance group was higher than in chemosensitivity group, differences were statistically significant in the above factors （ P〈0.001 ） . Conclusion PAK5

关 键 词：上皮性卵巢癌(EOC) PAK5 P-gp免疫组织化学 病理类型 化疗耐药 

分 类 号：R737.31[医药卫生—肿瘤]